Human Reproduction, Vol. 12, No. suppl_1, pp. 63-71, 1997
© 1997 European Society of Human Reproduction and Embryology
Perspective in the treatment of insulin resistance
Division of Diabetes, Nutrition and Metabolic Diseases, Department of Medicine, CHU Sail Tilman (B35) B-4000 Liège 1, Belgium
Improving the action of insulin is a relatively new concept in therapy. It should, however, become more and more important because of the rapid expansion of the insulin resistance syndrome (including upper body adiposity, glucose intolerance, hypertension, dyslipidaemia, etc.) in industrialized countries and its dramatic consequences for public health. Insulin sensitivity can be improved by non-pharmacological means, essentially reduction of excessive body weight, promotion of regular physical activity and modification of dietary habits, as well as, possibly, cessation of smoking and correction of subclinical magnesium deficiency. Currently available pharmacological means mainly include the biguanide compound metformin and possibly anti-obesity agents, such as (d-) fenfluramine, fluoxetine and benfluorex. New compounds aiming at improving the action of insulin are in development, especially the thiazolidinedione derivatives (e.g. troglitazone), known as ‘insulin sensitizers’. Treatment of insulin resistance may have important gynaecological applications, essentially in polycystic ovary syndrome and, possibly, after menopause. Hopefully, improving insulin sensitivity could ameliorate the cardiovascular prognosis of numerous individuals having some or all components of insulin resistance syndrome.
Key words: diabetes/insulin sensitivity/menopause/obesity/polycystic ovary syndrome/syndrome X